TY - JOUR T1 - Molecular and serological investigation of the 2021 COVID-19 case surge in Mongolian vaccinees JF - medRxiv DO - 10.1101/2021.08.11.21261915 SP - 2021.08.11.21261915 AU - Naranjargal J. Dashdorj AU - Naranbaatar D. Dashdorj AU - Mitali Mishra AU - Lisa Danzig AU - Thomas Briese AU - W. Ian Lipkin AU - Nischay Mishra Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/13/2021.08.11.21261915.abstract N2 - A surge in Covid-19 cases in Mongolia in March 2021 resulted in a government-mandated shutdown. This shutdown was relaxed in May 2021 as case numbers decreased and nationwide vaccination rates using Sinopharm, Covishield/AstraZeneca, Sputnik V, and Pfizer/BioNTech vaccines exceeded 50% of the population. Case rates increased again in early June 2021 in both vaccinated and non-vaccinated individuals. To determine whether the surge was due to the emergence of Delta or another variant, or vaccine failure, a rapid, opportunistic investigation was conducted that comprised virus sequence analysis of nasal swab samples from breakthrough cases and antibody assays of plasma from healthy vaccinees. More than 90% of breakthrough infections during the second case surge were due to the Alpha variant. Spike protein ELISA and SARS-CoV-2 neutralization assays data revealed large differences in plasma titers of antibodies to SARS-CoV-2, with mRNA vaccines eliciting higher titers than adenovirus-vectored or killed virus vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Skoll Foundation and the Onom Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request. ER -